Shouhui Group (2621.HK) — Deep Value Re-rating Setup After FY2025 Reset

by hkse-stock-research

Published: May 21, 2026 | Price: HKD 2.87 | Mkt Cap: HKD 650M (RMB 604M) Probability-Weighted FV: HKD 6.88 (+140% upside; bear case +26%) Catalyst: RAYS Capital Partners crossed 5.51% disclosure threshold at HKD 2.87 on entry sweep

1. Thesis in One Paragraph

Shouhui Group is China's second-largest online life & health insurance intermediary, trading at 3.0x adjusted P/E and 0.41x P/S after a -64% post-IPO drawdown driven by VC overhang and the 报行合一 (report-line consistency) commission compression policy. The 2025 annual results published March 25, 2026 confirm the operational trough is behind: first-year premium grew +49.9% YoY to over RMB 4.5B, total gross written premium +37% to RMB 11.2B, and H2 2025 revenue accelerated to +32% YoY. Management declared an inaugural dividend of HKD 0.14 per share (4.88% yield), signaling underlying cash generation. RAYS Capital Partners, a Hong Kong deep-value boutique with an explicit mandate for under-researched, over-looked, under-owned situations, just bought 5.51% at HKD 2.87. Reverse DCF shows the market is pricing in adjusted NP collapsing -61% by 2027 — a tail outcome inconsistent with the +37% premium momentum.

2. Verified Key Data (as of May 21, 2026)

3. FY2025 Actuals (published March 25, 2026)

Key insight: the revenue-premium gap is the alpha

Premium volume grew +37%; accounting revenue grew only +5.9%. The 31-point gap is 报行合一 commission rate compression. Once that policy anniversaries through (largely 2H2026), accounting revenue should catch up to the underlying business momentum.

4. Why RAYS Capital Bought

RAYS profile (per Preqin, SFC AXA409, company site):

• Hong Kong boutique, established 2010
• Founded by David Ruan: ex-CIO/Deputy CEO AXA Investment Managers HK; ex-Director Global Investments New-Alliance Asset Management; ex-Barclays Global Investors HK; previously ran USD 1B+ at Ajia Partners
• Explicit mandate: "Under-researched, over-looked, and under-owned deep value opportunities; long-term macro approach; special situations"
• SFC Type 4 (advising) + Type 9 (asset management) licensed
• Manages institutional and family office capital

Why 2621 fits the mandate:

RAYS bought 12.22M shares at HKD 2.87 (RMB 35.0M total). An affiliated fund filed simultaneously, taking combined ownership >10%. The fact RAYS could absorb 5.4% of outstanding in one sweep is itself a tell: VC sellers are unloading at distressed prices, creating the entry opportunity.

5. Peer Comparison

Median direct peer P/E excluding Zhongmiao and Fanhua: 8.9x. Shouhui at 3.0x represents a 66% discount. Mean reversion to median yields HKD 6.50–8.50 per share, consistent with the DCF output below.

6. Three-Scenario DCF (RMB millions unless noted)

Framework

• Methodology: exit multiple DCF on 2027E adjusted NP (Damodaran narrative-plus-numbers, exit P/E anchor given regulatory uncertainty)
• WACC: 14.5% (capital-light intermediary, no material debt; cost of equity = mature market RFR 4.3% + beta 1.2 × ERP 4.6% + country risk 1.5% + small-cap illiquidity premium 2.5%)
• Discount horizon: 2 years (current → year-end 2027)
• Net cash: estimated RMB 250M (unspent IPO proceeds RMB 71M + retained cash flow)
• Dividend treatment: HKD 0.14 base case assumed sustained 2 years (PV included)

Scenario results

Probability-weighted FV: HKD 6.88 (+140% from HKD 2.87)

Critically, even the bear case implies positive upside (+26%), suggesting the current price is below what a conservative outcome would justify.

Reverse DCF: what is HKD 2.87 pricing in?

At a 6x exit P/E (reasonable for distressed cyclical) and 14.5% WACC:

Market-implied 2027 adjusted NP: RMB 77M — a -61% collapse from FY2025 actual RMB 200M.

This requires:

1. Revenue declining materially through 2026–2027 (vs. actual +5.9% in 2025 with strong premium momentum)
2. Adjusted margin compressing to ~5% (vs. 13.6% actual 2025)
3. The dividend being unsustainable

None of these align with the operating trajectory disclosed in the March 25 annual results. The price reflects forced selling, not fundamentals.

Sensitivity (Base case FV, HKD)

FV holds above HKD 4.85 across the entire grid — current price below any reasonable cell.

7. Risks

1. VC lockup expiry overhang: Sequoia China, Matrix Partners, Xintian, Gopher Asset are pre-IPO investors with bet-on (对赌) clauses that triggered the IPO push. Lock-up expiry (typically 6–12 months post-listing, so around late 2025–mid 2026) may have already begun, explaining recent selling. Continued supply could cap re-rating in the near term.

2. 报行合一 policy further tightening: Regulator could mandate further commission rate caps. Margin compression from 38.1% to 32.9% in 2025 already material; further compression to 25–28% would damage the bull case.

3. Customer concentration: Prospectus disclosed elevated concentration of top insurers. Loss of a major insurer partner is single-name risk.

4. Traffic platform dependency: 58–63% of insurance transaction revenue paid out to channels (Douyin, Baidu, etc.) in 2022–2024. Platforms have asymmetric pricing power.

5. Dividend sustainability: HKD 0.14 dividend is the first ever; not yet established as recurring policy. Must verify in 2025 annual report whether a formal payout ratio policy was adopted.

6. Chinese ADR/HK small-cap discount: Structural valuation discount may persist longer than fundamentals warrant.

7. Dividend product economics unproven: The +341.5% FYP growth in dividend products is impressive on volume but the short-term commission rate is materially lower than long-term critical illness — profit dollars may lag revenue.

8. Position Sizing & Catalysts

Recommended sizing: 1.5–2.5% of portfolio. Asymmetric setup (bear +26%, base +135%, bull +262%) supports above-minimum size; liquidity constraints (HKD 650M market cap) and regulatory uncertainty cap upper bound.

Catalysts to monitor:

• 1H2026 interim results (~August 2026): need revenue growth above +15% YoY confirming 2H25 momentum extends
• Dividend recurrence: any guidance on payout policy in annual report supplements or AGM
• Further insider/institutional disclosure: HKEX disclosure of interests filings showing whether RAYS continues building position or new institutions enter
• Sell-side initiation: when first sell-side analyst initiates coverage (currently zero public coverage), the under-researched discount should compress

Position management:

• Entry: HKD 2.85–3.00 (RAYS print level + small premium)
• First trim level: HKD 5.50 (50% off base case FV)
• Stop loss consideration: HKD 2.30 (below bear case minus margin of safety)

9. Single-Leg Options Considerations

Hong Kong-listed equities have limited single-stock option markets; 2621.HK does not currently have listed options. Position must be executed in cash equity only. Liquidity check on the underlying: average daily turnover roughly HKD 0.5M–1.0M; building a meaningful position requires patient execution over 2–4 weeks via VWAP or similar.

10. Conclusion

Recommendation: Initiate Long position, sized 1.5–2.5%.

The setup combines several Damodaran/Kong framework signals:

1. Reverse DCF disconnect: market pricing -61% NP decline vs. operations showing +37% premium growth
2. Sophisticated insider validation: RAYS Capital, a 16-year-old deep-value specialist, sized 5.4% at HKD 2.87
3. Capital return signaling: 4.88% indicated dividend yield with first-ever payout declared
4. Trough confirmation: H2 2025 revenue +34% YoY confirms operational reset complete
5. Asymmetric payoff: bear case +26%, probability-weighted +140%

The primary risk is timing — VC overhang may persist for 6–12 months, suggesting this is a multi-quarter holding period rather than a near-term trade. Final dividend ex-date and AGM resolutions are intermediate-term catalysts to monitor.

Disclosure: This is a research note, not investment advice. Numbers verified against HKEX filings, the March 25, 2026 results announcement, and Chinese-language financial media (Sina Finance, Sohu, Stockstar, Investors Reports). Material errors should be flagged. All financials in RMB unless noted. HKD/CNY conversion at 0.93.